Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 19% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
1Q Revenues: $20.0 billion (+13%)
1Q Earnings: $4.4 billion (-1%)
Comments: Pharmaceutical sales were $9.8 billion in the quarter, up 19%. Domestic sales increased 10% and international sales were up 33%. Sales include the impact of Actelion Ltd. which contributed 7.6%, to worldwide operational sales growth. Remicade sales were down 17% to $1.4 billion in the quarter due to competition. Stelara sales were up 29% to $1.1 billion. Simponi sales were up 21% to $518 million. Edurant sales were up 41% to $210 million. Prezista sales were up 11% to $478 million. Invega Sustenna sales were up 15% to $696 million. Darzalex sales were $432 million, up 69%. Imbruvica sales were $587 million, up 44%. Zytiga sales were $845 million, up 62%. Velcade sales were up 12% to $313 million. Xarelto sales were $578 million, up 13%. Worldwide Consumer sales were $3.4 billion in the quarter, up 5%. Worldwide Medical Devices sales were $6.8 billion, up 7.5%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters